华东医药竞逐银屑病百亿市场 罗氟司特乳膏上市申请获受理

Core Viewpoint - The approval of Roflumilast cream (ZORYVE) by the National Medical Products Administration (NMPA) represents a significant advancement for patients with plaque psoriasis, offering a new treatment option in the Chinese market [1][2]. Company Summary - East China Pharmaceutical's subsidiary, Hangzhou Zhongmei East China Pharmaceutical Co., Ltd., has received the acceptance notice for the marketing application of Roflumilast cream (ZORYVE) 0.3% [1]. - Roflumilast is a highly selective non-steroidal phosphodiesterase-4 (PDE4) inhibitor, which has shown significant clinical advantages over previously approved topical psoriasis treatments [1][2]. - The cream is expected to enhance the company's core competitiveness in dermatology and innovative topical formulations, providing new momentum for long-term development [3]. Industry Summary - The psoriasis drug market in China has rapidly grown from $604 million in 2018 to $1.436 billion in 2022, with a compound annual growth rate (CAGR) of 24.2%, significantly outpacing global growth [3]. - The market size for psoriasis drugs in China is projected to reach 13.9 billion yuan in 2023 and is expected to grow to 89.4 billion yuan by 2032, with a CAGR of 59.1% [3]. - There is a substantial unmet clinical need for psoriasis treatments, indicating strong growth potential and development space in the Chinese market [2].